Home › Research › Treatments
Anti-amyloid immunotherapies for Alzheimer’s disease old people: eligibility and real life in a geriatric memory clinic in Lille (France)
Dominique Huvent‐Grelle, Nicolas HABIB, François L. Puisieux. La Revue de gériatrie, 2025-07-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
In 2022, 726 patients were included. The average age was 82.2 years, with a majority of women (68.5%). Most patients were accompanied (85.7%). They had multiple comorbidities and took multiple medications, primarily for cardiovascular diseases. For 613 patients (84.6%), the MMSE score was ≥ 22. In our population, 239 patients (32.9%) were diagnosed “MCI” (Mild Cognitive Impairment), and 147 (20.2%) “Alzheimer’s disease”. The vast majority (95.7%) of patients had undergone MRI. Of the 50 ‘eligible’ patients, 46 had no evidence of AD (amyloid PET or LP). Only 4 patients had undergone Lumbar Puncture, with positive AD biomarkers. None had undergone amyloid PET. Anti-amyloid immunotherapy involves only a small number of Alzheimer elderly patients. Further research is needed. The use of this therapy presents a significant challenge for geriatricians. It seems essential to develop a specific care pathway, create specific multidisciplinary case conferences, and establish a dedicated care pathway.
What this study adds
Evidence grade: Moderate
This is a trial of 726 participants. Among 726 patients in a geriatric memory clinic, only 50 were considered eligible for anti-amyloid immunotherapy, and of those 46 had no evidence of Alzheimer's disease on amyloid PET or lumbar puncture, so none had actually undergone amyloid PET. Reported effect size: 68.5%; 85.7%; 84.6%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Huvent‐Grelle, D., HABIB, N., & Puisieux, F. L. (2025). Anti-amyloid immunotherapies for Alzheimer’s disease old people: eligibility and real life in a geriatric memory clinic in Lille (France). La Revue de gériatrie. https://doi.org/10.62581/revgeri.21682
Vancouver
Huvent‐Grelle D, HABIB N, Puisieux FL. Anti-amyloid immunotherapies for Alzheimer’s disease old people: eligibility and real life in a geriatric memory clinic in Lille (France). La Revue de gériatrie. 2025. doi:10.62581/revgeri.21682.
BibTeX
@article{huventgrelle2025-972a008a,
author = {Huvent‐Grelle, Dominique and HABIB, Nicolas and Puisieux, François L.},
title = {{Anti-amyloid immunotherapies for Alzheimer’s disease old people: eligibility and real life in a geriatric memory clinic in Lille (France)}},
journal = {La Revue de gériatrie},
year = {2025},
doi = {10.62581/revgeri.21682},
url = {https://doi.org/10.62581/revgeri.21682}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The average age was 82.2 years, with a majority of women (68.5%).
- They had multiple comorbidities and took multiple medications, primarily for cardiovascular diseases.
- For 613 patients (84.6%), the MMSE score was ≥ 22.
- In our population, 239 patients (32.9%) were diagnosed “MCI” (Mild Cognitive Impairment), and 147 (20.2%) “Alzheimer’s disease”.
- The vast majority (95.7%) of patients had undergone MRI.
Why it matters
Among 726 patients in a geriatric memory clinic, only 50 were considered eligible for anti-amyloid immunotherapy, and of those 46 had no evidence of Alzheimer's disease on amyloid PET or lumbar puncture, so none had actually undergone amyloid PET. The authors conclude that anti-amyloid immunotherapy applies to only a small number of elderly Alzheimer's patients and that further research and a dedicated care pathway are needed.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Participants726
- Effect size68.5%; 85.7%; 84.6%
- Evidence strengthModerate
How this study scored 35/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 34 of the 97 points we could judge it on, which is 35 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (La Revue de gériatrie) |
| Journal's citation record | 0 / 4 | La Revue de gériatrie: journal h-index 9 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 726 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author François L. Puisieux: h-index 31 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 34 / 97 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 34 of the 97 points we could judge it on is 35 out of 100. |
| Total | 35 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.